EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Volumetric Nanodroplet‐Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform

Bar Glickstein iD, Mike Bismuth, Roni Gattegno, Tiran Bercovici, Oz Shaul, Ramona Aronovich, Galit Horn, Anat Globerson Levin, Yi Feng, Tali Ilovitsh iD

Small · 2025

DOI: 10.1002/smll.202411474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Bar Glickstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Nanoparticles, Neoplasms, Ultrasonic Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Marian Gertner Institute, National Natural Science Foundation of China, Ministry of Science and Technology, Israel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors hold promise, yet their efficacy in solid tumors is limited by the complex tumor microenvironment and the lack of immune cell infiltration. This study aims to enhance immunotherapy by combining anti PD‐1 checkpoint inhibition therapy with nanodroplet‐mediated histotripsy. The proposed method involves systemic injection of nanodroplets, which accumulate within tumors. These nanodroplets are then activated into cavitating gas bubbles using a rotating imaging probe, followed by low‐frequency ultrasound application. This process induces tumor fractionation, facilitating the shift of the tumor microenvironment from cold to hot. Tumor ablation results show extensive lesions within the cancerous tissues, demonstrating the effectiveness of the ablation treatment. The combined approach of nanodroplets, ultrasound and anti PD‐1 yielded a significant reduction in tumor growth compared to control groups. Immunohistochemistry analysis reveals an increase in F4/80+ macrophages and CD8+ T cells in the treated tumor group, indicating an enhanced immune response. F4/80+ macrophages reached 21.36% ± 3.4%, while CD8+ T‐cell recruitment achieved 6.76% ± 4.5%, representing a 6.8‐ and a 5.5‐fold increase compared to the control group, respectively. This approach demonstrates the potential to overcome key barriers in solid tumor treatment by combining precise mechanical disruption with systemic immune activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNanoparticlesNeoplasmsUltrasonic TherapyAnimalsMiceCell Line, TumorImmunotherapyTumor MicroenvironmentCD8-Positive T-LymphocytesHumansMice, Inbred C57BLMacrophages

Stichwörter der Autor:innen

cancer therapycheckpoint inhibitionfocused ultrasoundhistotripsyimmunotherapymechanical ablationnanodroplets

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • School of Electrical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • Immunology and Advanced CAR-T Cell Therapy Laboratory, Research & Development Department, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, 6423906, Israel.
  • Dotan Center for Advanced Therapies, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, 6423906, Israel.
  • The Key Laboratory of Biomedical Information Engineering of the Ministry of Education, Department of Biomedical Engineering, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.

ORCID-Profile: Bar Glickstein, Tali Ilovitsh

Förderung

  • Marian Gertner Institute
  • National Natural Science Foundation of China
  • Ministry of Science and Technology, Israel
  • Israel Science Foundation
  • Horizon 2020 Framework Programme

Zitieren

APA

Glickstein, B., Bismuth, M., Gattegno, R., Bercovici, T., Shaul, O., Aronovich, R., Horn, G., Levin, A. G., Feng, Y., & Ilovitsh, T. (2025). Volumetric Nanodroplet‐Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform. Small. https://doi.org/10.1002/smll.202411474

Vancouver

Glickstein B, Bismuth M, Gattegno R, Bercovici T, Shaul O, Aronovich R, et al. Volumetric Nanodroplet‐Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform. Small. 2025. doi:10.1002/smll.202411474

BibTeX
@article{Glickstein2025,
  author = {Glickstein, Bar and Bismuth, Mike and Gattegno, Roni and Bercovici, Tiran and Shaul, Oz and Aronovich, Ramona and Horn, Galit and Levin, Anat Globerson and Feng, Yi and Ilovitsh, Tali},
  title = {Volumetric Nanodroplet‐Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202411474}
}
Kostenlos starten →